XVIII International Symposium on Respiratory Viral Infections
March 31 – April 2, 2016
Lisbon, Portugal

Preliminary Program
As of February 6, 2016

Chairs:
Abdullah Brooks  Centre for Vaccine Sciences (ICDDR,B) Dhaka, Bangladesh; The Bloomberg School for Public Health, Department of International Health, Johns Hopkins University, Baltimore, Maryland, United States
Arnold Monto  Thomas Francis Jr Professor of Epidemiology, University of Michigan, Ann Arbor, Michigan, United States

Scientific Advisory Board:
Rick Bright  HHS/OS/ASPR/BARDA, Washington, District of Columbia United States (accepted)
Menno de Jong  Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (accepted)
Janet Englund  University of Washington, Seattle, Washington, United States (accepted)
Daniel Feikin  Division of Viral Disease, CDC, Atlanta, Georgia, United States (accepted)
Sebastian Johnston  National Heart & Lung Institute, Imperial College, London, United Kingdom (accepted)
Yoshihiro Kawaoka  University of Tokyo, Tokyo, Japan; University of Wisconsin, Madison, Wisconsin, United States (accepted)
Kathy Neuzil  University of Maryland School of Medicine, Baltimore, Maryland, United States (accepted)
Albert Osterhaus  Artemis One Health, Utrecht, The Netherlands; and University Veterinary Medicine Hannover, Germany (accepted)
Malik Peiris  University of Hong Kong, Hong Kong SAR, People’s Republic of China (accepted)
Preliminary Program

Wednesday, March 30, 2016
15.00 – 18.00  Registration

Thursday, March 31, 2016 - Day One
07.00   Registration Opens
09.00   Welcome and Introduction to Keynote
09.10 – 10.00 Keynote Address: Influenza Mismatch: Where do We Go? Barriers to Influenza Vaccine – Derek Smith, University of Cambridge, Cambridge, United Kingdom (accepted)

Session I   Influenza – Chair: Derek Smith, University of Cambridge, Cambridge, United Kingdom
10.00 – 10.25 Immune Responses to Influenza Vaccine in the Elderly – Richard Aspinall, Director, Health & Wellbeing Academy, Anglia Ruskin University, Chelmsford, United Kingdom (accepted)
10.25 – 10.50 Are Universal Vaccines the Solution to Strain Selection Problems? – Jacqueline Katz, Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States (accepted)
10.50 – 11.20 Coffee break
11.20 – 11.45 Risk Factors for Influenza Hospitalization: The Canadian Experience – Melissa Andrew, Division of Geriatric Medicine, Dalhousie University, Halifax, Nova Scotia, Canada (accepted)
11:45 - 12:05 Oral Presentation
Mutational Landscape of Highly Pathogenic Influenza A(N5N1) Virus Populations under Combination Therapy with Oseltamivir and T-705
Elena A. Govorkova, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
12:05 – 12:25 Oral Presentation – Young Investigator Award Recipient
Selective Bottlenecks Shape Evolutionary Pathways Taken During Mammalian Adaptation of A 1918-like Avian Influenza Virus
Louise Moncla, University of Wisconsin-Madison, Wisconsin, United States
12.25 – 14.00 Lunch
### XVII International Symposium on Respiratory Viral Infections
#### March 31 – April 2, 2016
#### Lisbon, Portugal

**Preliminary Program**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00 – 14:20</td>
<td><strong>Oral Presentation</strong>&lt;br&gt;Trivalent Inactivated Influenza Vaccine Efficacy Among Young Children in an Urban Tropical Setting&lt;br&gt;Melissa Rolfes, Centers for Disease Control and Prevention. Atlanta, Georgia, United States</td>
</tr>
<tr>
<td>14.20 – 14.40</td>
<td><strong>Oral Presentation</strong>&lt;br&gt;ViroSpot Microneutralization Assay for Antigenic Typing of Influenza Viruses&lt;br&gt;C.A. van Baalen, Viroclinics Biosciences B.V., Rotterdam, The Netherlands</td>
</tr>
</tbody>
</table>

**Session II** **Vaccination – Chair: Arnold Monto, Thomas Francis Jr Professor of Epidemiology, University of Michigan, Ann Arbor, Michigan, United States**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.40 – 15.05</td>
<td>Universal Vaccines: State of the Art – Rick Bright, Director of the Influenza Division, Biomedical Advanced Research and Development Authority (BARDA), Washington, District of Columbia, United States <em>(accepted)</em></td>
</tr>
<tr>
<td>15.05 – 15.30</td>
<td>Intervention Strategies for MERS: Where do we Stand? – Bart Haagmans, Erasmus MC, Rotterdam, the Netherlands <em>(accepted)</em></td>
</tr>
<tr>
<td>15.30 – 16.00</td>
<td><strong>Coffee Break</strong></td>
</tr>
<tr>
<td>16.00 – 16.25</td>
<td>Pandemic Influenza: Advances in Virus Biology and Vaccine Development - Kanta Subbarao, National Institute for Allergy and Infectious Diseases/National Institute of Health (NIAID/NIH), Bethesda, Maryland, United States <em>(accepted)</em></td>
</tr>
<tr>
<td>16.50 – 17.15</td>
<td>Influenza Vaccination and Public Health – Richard Pebody, Department of Respiratory Diseases, Health Protection Agency, London, United Kingdom <em>(accepted)</em></td>
</tr>
<tr>
<td>17.15 – 17.35</td>
<td><strong>Oral Presentation</strong>&lt;br&gt;Impact of Statin Use on Influenza Vaccine Effectiveness against Laboratory Confirmed Influenza&lt;br&gt;Huong McLean, Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States</td>
</tr>
<tr>
<td>17.35 – 17.55</td>
<td><strong>Oral Presentation</strong>&lt;br&gt;The Confounded Effects of Age and Exposure History in Response to Influenza Vaccination&lt;br&gt;Ana Mosterin Hopping, Cambridge University, Cambridge, United Kingdom</td>
</tr>
<tr>
<td>18.00 – 19.30</td>
<td><strong>Welcome Reception</strong></td>
</tr>
</tbody>
</table>
Friday April 1, 2016 – Day 2

08:30 – 09:00  Workshop: Opportunities and Strategies for Funding of Scientific Projects - Frank Dege, Erasmus MC, Rotterdam, The Netherlands (accepted)

Session III  Pathogens, Clinical Intervention & Antivirals/Antibodies – Chair: Menno de Jong, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (accepted)

09:00 – 09:25  Update on Patient Management of H7N9 with Single vs Double Dose Oseltamivir – George Gao, Chinese Center for Disease Control and Prevention, Beijing, China (accepted)

09.25 – 09.50  Consensus Management of Patients: Findings on the use of Steroids, Convalescent Plasma... – Menno de Jong, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (accepted)

09.50 – 10.15  Oral Presentation
Nitazoxanide, a Broad-Spectrum Antiviral for Treatment of Respiratory Viral Infections
Jean-Francois Rossignol, The Romark Institute for Medical Research, Tampa, Florida, United States

10.15 – 10.45  Coffee Break

10.45 – 11.05  Oral Presentation
Targeting the Non-structural Protein 1 of Influenza A Virus for the Development of a Broad-spectrum Antibody-based Immunotherapy
Yee-Joo Tan, Yong Loo Lin School of Medicine and Institute of Molecular and Cell Biology, Singapore

11.05 - 11.25  Oral Presentation
A Phase I Study to Evaluate the Safety and Pharmacokinetics (PK) of MEDI8852 in Healthy Adults
Omar Ali, MedImmune, Gaithersburg, Maryland, United States

11.25 - 11.45  Oral Presentation
Reinventing the Common Cold Institute for the 21st Century
Robert Lambkin-Williams, hVIVO, London, United Kingdom

11.45 - 12.05  Oral Presentation
Antiviral Activity of Nitazoxanide Against Paramyxoviridae Infection: Effect on the Fusion (F) Protein
M. Gabriella Santoro, University of Rome Tor Vergata, Rome, Italy

12.05 – 14.05  Lunch
 Session IV  

**Respiratory Viral Exacerbation of Airway Disease, National Heart & Lung Institute, Imperial College, London, United Kingdom (accepted)** and **Ross P. Walton, National Heart & Lung Institute, Imperial College, London, United Kingdom (accepted)**

14.05 – 14.30  
Novel Mechanisms of Rhinoviruses Induced Asthma Exacerbations – Sebastian Johnston, National Heart & Lung Institute, Imperial College, London, United Kingdom (accepted)

14.30 – 14.55  
Viruses that should be Targeted for Prevention: Their Potential Impact on Longer Term Disease Burden - Louis Bont. University of Utrecht, Utrecht, The Netherlands (accepted)

14.55 – 15.20  
COPD Complications of Influenza - Tom Wilkinson, University of Southampton, United Kingdom (accepted)

15.20 – 15.50  
Coffee Break

15.50 – 16.10  
**Oral Presentation – Young Investigator Award Recipient**

Impaired Dendritic Cell Recruitment and Anti-Viral Function in Asthmatic Patients Following Rhinovirus Infection  
Aoife Cameron, Imperial College London, NHLI, London, United Kingdom

16.10 – 16.30  
**Oral Presentation**

Phenotypic Analysis of Pulmonary Innate Lymphoid Cells following Experimental Rhinovirus Challenge in Asthma  
Jaideep Dhariwal, Imperial College London, NHLI, London, United Kingdom

16.30 – 16.50  
**Oral Presentation**

The Dynamics of Respiratory Syncytial Virus (RSV) Replication in Infants Reveals an Age-related Functional Maturation of the Antiviral Immune Response  
John DeVincenzo, University of Tennessee College of Medicine and the Children's Foundation Research Institute at LeBonheur Children's Hospital, Memphis, Tennessee, United States

16.50 – 17.10  
**Oral Presentation**

Adenovirus Type 4 Respiratory Infections among Civilians in the Northeast United States: Documentation of Recent Activity of an Underestimated Pathogen  
Adriana Kajon, Lovelace Respiratory Research Institute, Albuquerque, New Mexico, United States

17.10 – 17.40  
Poster Review – Albert Osterhaus, Artemis One Health, Utrecht, The Netherlands; and University Veterinary Medicine Hannover, Germany (accepted)

17.45 – 18.45  
Poster Session Reception
Saturday, April 2, 2016 – Day Three

Session V  One Health: Animal/Human/Environmental Interface – Chair: Albert Osterhaus, Artemis One Health, Utrecht, The Netherlands; and University Veterinary Medicine Hannover, Germany (accepted)

09.00 – 09.25  New Human Pathogens: From Identification to Intervention – Albert Osterhaus, Artemis One Health, Utrecht, The Netherlands; and University Veterinary Medicine Hannover, Germany (accepted)

09.25 – 09.50  Update on Ebola – Jean-Jacques Muyembe-Tamfum, University of Kinshasa, Democratic Republic of the Congo (accepted)

09.50 – 10.15  Outbreaks of Avian H5 in the United States – David Swayne, Director, Agricultural Research Service, United States Department of Agriculture, Athens, Georgia, United States (accepted)

10.15 – 10.45  Coffee Break

10.45 – 11.30  Panel Discussion – Albert Osterhaus, Artemis One Health, Utrecht, The Netherlands; and University Veterinary Medicine Hannover, Germany (accepted); Jean-Jacques Muyembe-Tamfum, University of Kinshasa, and David Swayne, USDA/Agricultural Research Service, Athens, Georgia, United States (accepted)

11.30 – 13.30  Lunch

Session VI  RSV – Chair: Daniel Feiken, Division of Viral Disease, Centers for Disease Control and Prevention, Atlanta, Georgia, USA (accepted)

13.30 – 13.55  New Developments in RSV – TBD

13.55 – 14.20  RSV and Viral CoInfections – Emily T Martin, School of Public Health, University of Michigan, Ann Arbor, Michigan United States (accepted)

14.20 – 14.45  Rapid Progress and Human Proofs of Concept in RSV Antiviral Therapeutics – John DeVincenzo, University of Tennessee School of Medicine and Le Bonheur Children's Hospital, Children's Foundation Research Institute, Memphis, Tennessee, United States (accepted)

14.45 – 15.15  Coffee Break

15.15 – 15.35  Oral Presentation
Clinical and Socioeconomic Burden of Respiratory Syncytial Virus Infection in Children in the Community
Terho Heikkinen, University of Turku and Turku University Hospital, Finland

15.35 – 15.55  Oral Presentation
Transmission of RSV in a Cohort of Households with Children over 2 Surveillance Seasons
Ryan E. Malosh, University of Michigan School of Public Health, Ann Arbor, Michigan, United States

15.55 – 16.15

Oral Presentation

The Use of the Human Viral Challenge Model as Part of a Long Term Program of Work to Better Understand Respiratory Viruses and their Interaction with the Human Host

Robert Lambkin-Williams, hVivo Services Ltd., London, United Kingdom

16.15 – 16.30

Closing Remarks